Skip to main content
61°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by CEL-SCI Corporation
< Previous
1
2
Next >
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
September 16, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
September 10, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance
September 04, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
August 15, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Announces Closing of $10.8 Million Offering
July 29, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Announces Pricing of $10.8 Million Offering
July 26, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results
July 26, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Appoints Robert Watson as Chairperson of the Board
July 08, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
June 18, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
June 06, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
May 16, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
May 08, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
April 23, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
March 19, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Corporation Issues Letter to Shareholders
March 06, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
February 15, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
February 13, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
February 09, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
February 06, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
January 31, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
December 22, 2023
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
December 04, 2023
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
November 20, 2023
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
November 16, 2023
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Issues Letter to Shareholders
October 30, 2023
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals
October 24, 2023
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023
October 23, 2023
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production
October 19, 2023
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer
October 05, 2023
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer
September 26, 2023
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.